Our Science - Small-Molecule Drug Discovery
Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics. We also choose areas of unmet medical need and target a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects. The results of the CBL-514 clinical trial could potentially compete in the more than $100 billion prescription fat reduction market with further advances in the drug development process.
Our Focus - Aesthetics Medical & Inflammatory Disease
Caliway is currently evaluating the safety and efficacy of CBL-514, a first-in-class agent that induces adipocyte apoptosis and reduces subcutaneous fat in the targeted area.
Independently developed by Caliway, CBL-514 is under multiple studies for multiple indications including local fat reduction, cellulite, Dercum’s disease, and lipoma treatment. The Phase IIa clinical trial of CBL-514 for non-invasive fat reduction indication was completed in November 2020. The study has met its primary efficacy endpoint with a significant statistical difference (p<0.00001) and superior safety and tolerability profiles.
Caliway’s other candidate products’ indications include osteoarthritis, central obesity, non-alcoholic fatty liver disease, hyperpigmentation, and skin aging.
Visions
To become the international innovative pharmaceutical leader in the fields of medical aesthetics and inflammatory disease.
Mission
Our Mission is to break through the current technical difficulties with the company's research and development innovation of new drugs, and to create better treatment options to increase the quality of life.
Our Global Strategy For New Drugs
In addition to initiating clinical trials of drugs and indications that require a shorter development period to accelerate the development licensing timeline, Caliway also targets rare disease indication to speed up the clinical trial application and reviewing process.
Regarding the layout of new drug patents, Caliway has successively applied for patent protection in numerous countries worldwide since 2015. Of 79 patent applications filed, more than 86% of them have been approved.
